Adam Hutchings

Statistics

Publications

Citations

680

H-Index

Active since

1987

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

Bocconi University

Heidelberg University

University College London

Immodulon Therapeutics (United Kingdom)

Adam Hutchings is an author at Bristol-Myers Squibb (Switzerland) specializing in pharmaceutical policy, orphan drug designation, and pharmaceutical economics.

ORCID

Publications per year

1987–2022

Publications

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020

Carina Schey, Tsveta Milanova, Adam Hutchings · Orphanet Journal of Rare Diseases · 2011 · 132 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines

Jon Sussex, Pierrick Rollet, Martina Garau et al. · Value in Health · 2013 · 109 citations

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +15

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Lieven Annemans, Ségolène Aymé, Yann Le Cam et al. · Orphanet Journal of Rare Diseases · 2017 · 107 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +17

The Longitudinal Examination of Arthritis Pain (LEAP) study: relationships between weekly fluctuations in patient-rated joint pain and other health outcomes.

Adam Hutchings, Michael Calloway, Ernest Choy et al. · PubMed · 2007 · 100 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Estimating the budget impact of orphan drugs in Sweden and France 2013–2020

Adam Hutchings, Carina Schey, Richard Dutton et al. · Orphanet Journal of Rare Diseases · 2014 · 44 citations · Full text

Public Affairs, Pharmaceutical Policy, Budget Impact Analysis +16

1–5 of 14